101 related articles for article (PubMed ID: 27525951)
1. Target fishing of glycopentalone using integrated inverse docking and reverse pharmacophore mapping approach.
Gurung AB; Ali MA; Bhattacharjee A; Al-Anazi KM; Farah MA; Al-Hemaid FM; Abou-Tarboush FM; Lee J; Kim SY; Al-Anazi FS
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525951
[TBL] [Abstract][Full Text] [Related]
2. Glycopentalone, a novel compound from Glycosmis pentaphylla (Retz.) Correa with potent anti-hepatocellular carcinoma activity.
Sreejith PS; Asha VV
J Ethnopharmacol; 2015 Aug; 172():38-43. PubMed ID: 26068427
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking of the anticancer bioactive compound proceraside with macromolecules involved in the cell cycle and DNA replication.
Gurung AB; Ali MA; Bhattacharjee A; AbulFarah M; Al-Hemaid F; Abou-Tarboush FM; Al-Anazi KM; Al-Anazi FS; Lee J
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173346
[TBL] [Abstract][Full Text] [Related]
4. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Konidala KK; Bommu UD; Pabbaraju N
J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
[TBL] [Abstract][Full Text] [Related]
5. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
7. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
[TBL] [Abstract][Full Text] [Related]
8. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W; Rungrotmongkol T; Hannongbua S
J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
PLoS One; 2021; 16(7):e0254035. PubMed ID: 34260631
[TBL] [Abstract][Full Text] [Related]
11. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
12. Study on Wangzaozin-A-Inducing Cancer Apoptosis and Its Theoretical Protein Targets.
Chen J; Wang S; Lu X
Technol Cancer Res Treat; 2016 Aug; 15(4):589-96. PubMed ID: 26082454
[TBL] [Abstract][Full Text] [Related]
13. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
15. Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach.
Chagaleti BK; Saravanan V; Vellapandian C; Kathiravan MK
RSC Adv; 2023 Nov; 13(48):33770-33785. PubMed ID: 38019988
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
17. Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.
Basati G; Saffari-Chaleshtori J; Abbaszadeh S; Asadi-Samani M; Ashrafi-Dehkordi K
Curr Drug Res Rev; 2019; 11(2):135-141. PubMed ID: 31875784
[TBL] [Abstract][Full Text] [Related]
18. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
20. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
